Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

I originally laid out a very compelling thesis for buying Regeneron when the share price was below 50, and came very close to buying it but the stock never met my arbitrary GBMB threshold. Now I find myself buying 30 shares for the #zzporte collaboration at 280, which is rather infuriating. Nevertheless, it's a good reminder that one of the psychological inhibitors of outperformance is reluctance to buy a stock just because a low was missed. Stocks shouldn't be bought just because they're going up, but they shouldn't be boycotted for that reason either.

Aside from the massive sales outperformance of Eylea, Regeneron has numerous late stage compounds in development including sarilumab for rheumatoid arthritis and alirocumab for hypercholesterolemia. They are also in late stage trials to broaden the indications for Eylea. Now that quarterly revenues are approaching half a billion dollars and the market cap has passed 27 billion, I don't feel well-qualified to make a fair value assessment so I'm limited to following Portefeuille's recommendation here.

Still has lots of gas in the tank to go higher

Very well run, finally a marketable product in Eylea. Great pipeline. I've owned since 1997, mainly because Dr. Roy Vagelos got invovled after retiring from Merck. He attracted a lot of early funding. They comapny is expanding their R&D and headquaters facility in Tarrytown and adding 400 to staff. Plenty of funding deals available for them now.

Killer pipeline, great management.

Strong uptrend, can't fight it right now. Recommend buy on a pullback.

My brother-in-law's son recently got a job there.

This is my big, actually biggest pick ever. I've been watching REGN for the past 2 years when it caught my eye by surging 50% in a couple days. I shorted it and made a big windfall and have watched it ever since. Anyways, this stock has much in common with NFLX and GMCR in that it meets three critical criteria

1. Its a midcap
2. It has a blockbuster product
3. It's had a huge runnup that pushed it past a 100 PE ratio

What happened to NFLX? What happened to GMCR? Well, both of them went from being midcaps with huge runups at over 100 PE to returning to their 5 year moving average. And both of those bubbles popped in a period of six months or less. I think that Regeron with repeat this pattern. I don't know when the bubble will pop, but I think the 100 PE ratio is a good pin-prick. Unfortunately, a 100 PE ratio can ride a stock as it goes up due to increasing earnings. The final indicator is the tone of the Head Man. Like Reed Hastings and the CEO of GMCR, Len Schleifer (or however its spelled) has done what all CEO's do when they are out of ideas. He's trumping up his other products that are nowhere close to his blockbuster and he's talking about oversea's sales. Good luck. Remember how GMCR said they'd be releasing a bunch of new K-Cups? Yeah, neither do anyone else. Remember when Reed Hastings started talking about overseas sales? Yeah, right before the stock went from $250 to $100 in 3 months.... earnings are released this February and I'm going to go full retard and buy a bunch of puts because its actually a safe bet at this point. REGN @ $40 by July

break out tf

Extremely overvalued biotech!

It was picked by www.hechtsoft.de Trade Alerts.

more jul12 long term plays

sell wholefoods & buy arden group (gelsons markets)
sell regeneron & infinity pharmaceuticals

high relative strenght

There are currently 30 REGN shares in my fund with break-even of around -$401.09, thus the REGN position is in the green by around 30 * ($140.35 - (-$401.09)) = $16243.20.

http://caps.fool.com/Blogs/fund-trades/727816.
http://twitter.com/portefeuillefun.

Biopharma Bubble. They have a great new drug and speculation has sent them soaring. One problem though: Drug companies shouldn't be valued like other companies. With nothing else really in the pipeline, this drugmaker will come back to Earth.

http://www.cnbc.com/id/46300316

$9.7B? Lots of obstacles, including Lucentis, Avastin, payers, etc., and the market is acting like they've already hit huge numbers. Strange self-limiting value prop on this, they had to develop it based on decreased injection frequency rather than efficacy. It worked, but the better the drug is at preventing re-injection the less $ they make. Will be interesting to watch how they adjust the price as they begin to see how often docs actually give injections in the clinic vs. what they saw in their trials.

Biotech's newest darling will come back to earth. Eylea is a good drug, but there's too much sales baked in to make it a good deal at this point.

just had drug approved

Very strong pipeline, with some exciting results due out at the end of this year.

bullish